Skip to Primary Navigation

HHS launches SURPASS to accelerate clinical trials and drug R&D

A woman looking in a microscope wearing a white lab coat in a lab.
Photo: H. Armstrong Roberts/ClassicStock/Getty Images

The program addresses longstanding challenges in clinical development, where bringing a new drug or biologic to market can take over a decade.

Moving to make clinical trials speedier, more efficient, and less difficult for patients, the US Department of Health and Human Services (HHS) has announced a new program and three supporting initiatives.

Launched through the Advanced Research Projects Agency for Health (ARPA-H), HSS launched the Simulation-augmented, Real-time Platform Adaptive Seamless Trials

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience